<DOC>
	<DOCNO>NCT00036192</DOCNO>
	<brief_summary>The purpose study assess safety efficacy FK614 type 2 diabetic subject receive sulfonylurea ( SU ) monotherapy .</brief_summary>
	<brief_title>Trial FK614 Type 2 Diabetics Inadequately Controlled Sulfonylurea</brief_title>
	<detailed_description>This prospective randomized , double-blind , placebo control , parallel group , Phase 2 study . Subjects meet selection criterion randomly assign receive 12 week twice daily ( BID ) dose FK614 placebo . Enrollment study approximately 200 patient .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>Inclusion Criteria Has history type 2 diabetes mellitus least 1 year Has take current sulfonylurea ( SU ) least 3 month . Subjects currently take metformin may eligible switch . Has receive oral antidiabetic medication SU take regularly prescribed insulin least 3 month Exclusion Criteria Has type 1 diabetes mellitus Has uncontrolled hypertension , i.e. , systolic BP &gt; 170 diastolic BP &gt; 95 mm Hg . History congestive heart failure</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>